Evommune

It is estimated that 60% of Americans live with at least one chronic inflammatory disease and it is expected that the prevalence will increase steadily over the next 30 years. Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a significantly reduced quality of life. Evommune’s focus is the discovery and development of unique therapies that help patients with chronic inflammatory diseases. We are evaluating multiple known and novel targets addressing both adaptive and innate immunity. Utilizing a unique screening platform, we identify molecules that are differentiated and that have a greater probability of being effective in treating patients. Our technology, coupled with a team with an extensive track record of successfully developing new medicines, will help accelerate the R&D process so that we can more quickly serve people with inflammatory diseases.